• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >A Study on TRUS-Guided Prostatic Biopsy and its Correlation with Serum PSA, Gleason Score and Grade-Grouping in a Tertiary Care Centre of Eastern India
【24h】

A Study on TRUS-Guided Prostatic Biopsy and its Correlation with Serum PSA, Gleason Score and Grade-Grouping in a Tertiary Care Centre of Eastern India

机译：印度东部三级护理中心TRUS指导的前列腺活检及其与血清PSA，Gleason评分和等级分组的相关性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adenocarcinoma of the prostate may be clinically suspected based on elevated serum PSA (Prostate Specific Antigen) and/or abnormal digital rectal examination. Serum PSA has been used in prostatic carcinoma screening and for diagnostic, therapeutic and prognostic purposes.Aim: To evaluate the role of serum PSA to differentiate between benign and malignant pathology of prostate diagnosed by Transrectal Ultrasound (TRUS) guided prostatic core biopsy with special emphasis on its correlation with risk stratification based on Gleason score and Grade grouping system.Materials and Methods: Total 45 cases of Prostatic core biopsy specimens of the patients where serum PSA value was known were included in this cross-sectional observational study. Biopsy specimens were processed for routine Haematoxylin-Eosin stain and diagnosed as benign or malignant by histopathological examination along with Gleason score and Grade-Grouping was done. The comparison of PSA value between benign and malignant cases along with its significance of association with higher Grade-Grouping was statistically judged by unpaired t-test.Results: Out of total 45 cases, 23 (51.11%) cases showed presence of adenocarcinoma and rest 22 cases were of benign pathology. Mean PSA value (ng/mL) was significantly higher in malignant cases i.e., 58.47 (±22.191) compared to benign cases i.e., 3.45 (±0.987). However, in malignant cases which have been categorised as low to intermediate risk group (Gleason score <8) and high risk group (Gleason score =8), the mean PSA values (ng/mL) were 58.75 and 58.18 respectively and they were not so statistically significant (p-value=0.95) to differentiate between these two groups.Conclusion: Estimation of serum PSA has got definite significance in differentiating benign cases from malignant cases in prostatic core biopsy specimens (TRUS guided). But in cases of prostate adenocarcinoma while considering the disease stage based on Gleason Score and Grade-grouping, the serum PSA value has got no statistically significant role.
机译：根据血清PSA（前列腺特异性抗原）升高和/或直肠指检异常，可能会在临床上怀疑前列腺腺癌。血清PSA已用于前列腺癌的筛查以及诊断，治疗和预后的目的。目的：评估血清PSA在经直肠超声（TRUS）指导的前列腺核心活检所诊断的前列腺良性和恶性病理之间的作用。 材料与方法：本断面观察包括45例已知血清PSA值的患者的前列腺核心活检标本。研究。处理活检标本进行常规苏木精-伊红染色，并通过组织病理学检查，格里森评分和等级分组将其诊断为良性或恶性。通过未配对t检验统计判断良性和恶性病例的PSA值比较及其与较高等级分组的关联性。结果：在45例病例中，有23例（51.11％）显示存在PSA值。腺癌和其余22例均为良性病理。与良性病例（3.45（±0.987））相比，恶性病例的平均PSA值（ng / mL）显着更高，即58.47（±22.191）。但是，在分为低危至中危组（格里森评分<8）和高危组（格里森评分= 8）的恶性病例中，平均PSA值（ng / mL）分别为58.75和58.18，而没有因此，具有统计学意义（p值= 0.95）以区分这两组。结论：在前列腺癌核心活检标本中（TRUS指导），血清PSA的估计在区分良性病例和恶性病例中具有确定的意义。但是在前列腺癌的情况下，根据格里森评分和等级分组考虑疾病分期，血清PSA值没有统计学意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号